<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921828</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-Celgene-JP-PMS-002</org_study_id>
    <nct_id>NCT02921828</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy of Pomalyst速 Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg</brief_title>
  <official_title>Pomalyst速Capsules Special Use-results Surveillance (All-case Surveillance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Planned enrollment period One year (The planned number of patients to be enrolled is set
           to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in
           RevMate速, enrollment using the Registration Form of the surveillance will be completed
           at the time when the planned number of patients to be enrolled is reached. During a
           period until conditions for approval are removed, a system enabling to retrospectively
           collect appropriate information based on patient data from RevMate速 will be, as
           necessary, maintained.

        2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the
           start date of release of Pomalyst
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Anticipated">May 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1149</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Multiple myeloma patients who received Pomalyst</arm_group_label>
    <description>Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst
        will be targeted in this surveillance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Among relapsed or refractory multiple myeloma patients, all patients who received
             Pomalyst will be targeted in this surveillance.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoko Matsui</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shinko Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pomalyst</keyword>
  <keyword>Teratogenicity</keyword>
  <keyword>bone marrow suppression</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>infection</keyword>
  <keyword>tumour lysis syndrome</keyword>
  <keyword>somnolence</keyword>
  <keyword>depressed level of consciousness</keyword>
  <keyword>confusion</keyword>
  <keyword>fatigue</keyword>
  <keyword>dizziness</keyword>
  <keyword>acute renal failure</keyword>
  <keyword>heart failure</keyword>
  <keyword>arrhythmia</keyword>
  <keyword>interstitial pneumonia</keyword>
  <keyword>hypersensitivity</keyword>
  <keyword>hepatic function disorder</keyword>
  <keyword>jaundice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

